On the other hand, patients with ALL harboring almost incurable translocations, such as TCF3/HLF-fusion, are also directly eligible for receiving blinatumomab upfront, as these patients are known to display a high rate of treatment failure with conventional chemotherapy [51]. This evidence concerns the gene TCF3 and acute lymphoblastic leukemia.